A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

Kitching, 1998 Smith, 1978, Low dose steroids and clinical relapse in Crohn's disease: a controlled trial, Gut, 19, 606, 10.1136/gut.19.7.606 Bergman, 1976, Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease, Scand J Gastroenterol, 11, 651, 10.1080/00365521.1976.12097167 Anthonisen, 1974, The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study, Scand J Gastroenterol, 9, 549, 10.1080/00365521.1974.12096873 Lennard-Jones, 1977, Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial, Gut, 18, 69, 10.1136/gut.18.1.69 Rhodes, 1971, Controlled trial of azathioprine in Crohn's disease, Lancet, 2, 1273, 10.1016/S0140-6736(71)90598-8 Klein, 1974, Treatment of Crohn's disease with azathioprine: a controlled evaluation, Gastroenterology, 66, 916, 10.1016/S0016-5085(74)80166-6 Willoughby, 1971, Controlled trial of azathioprine in Crohn's disease, Lancet, 2, 944, 10.1016/S0140-6736(71)90268-6 Rosenberg, 1975, A controlled trial of azathioprine in Crohn's disease, Am J Dig Dis, 20, 721, 10.1007/BF01070829 O'Donoghue, 1978, Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease, Lancet, 2, 955, 10.1016/S0140-6736(78)92524-2 Winship, 1979, National Cooperative Crohn's Disease Study: study design and conduct of the study, Gastroenterology, 77, 829, 10.1016/0016-5085(79)90383-4 Best, 1976, Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study, Gastroenterology, 70, 439, 10.1016/S0016-5085(76)80163-1 Best, 1979, Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI), Gastroenterology, 77, 843, 10.1016/0016-5085(79)90384-6 de Dombal, 1987, IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease, Gut, 28, 474, 10.1136/gut.28.4.474 Cook, 1987, Patients with irritable bowel syndrome have greater pain tolerance than normal subjects, Gastroenterology, 93, 727, 10.1016/0016-5085(87)90434-3 Bernstein, 1996, Rectal afferent function in patients with inflammatory and functional intestinal disorders, Pain, 66, 151, 10.1016/0304-3959(96)03062-X Chang, 2000, Perceptual responses in patients with inflammatory and functional bowel disease, Gut, 47, 497, 10.1136/gut.47.4.497 Isgar, 1983, Symptoms of irritable bowel syndrome in ulcerative colitis in remission, Gut, 24, 190, 10.1136/gut.24.3.190 Harvey, 1980, A simple index of Crohn's disease activity, Lancet, 1, 514, 10.1016/S0140-6736(80)92767-1 Myren, 1984, The O.M.G.E. Multinational Inflammatory Bowel Disease Survey 1976-1982. A further report on 2,657 cases, Scand J Gastroenterol Suppl, 95, 1, 10.1080/00365521.1984.12199901 Wright, 1985, A simple clinical index of Crohn's disease activity—the Cape Town index, S Afr Med J, 68, 502 Present, 1980, Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study, N Engl J Med, 302, 981, 10.1056/NEJM198005013021801 van Hees, 1980, An index of inflammatory activity in patients with Crohn's disease, Gut, 21, 279, 10.1136/gut.21.4.279 Summers, 1979, National Cooperative Crohn's Disease Study: results of drug treatment, Gastroenterology, 77, 847, 10.1016/0016-5085(79)90385-8 Malchow, 1984, European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment, Gastroenterology, 86, 249, 10.1016/0016-5085(84)90409-8 Rutgeerts, 1994, A comparison of budesonide with prednisolone for active Crohn's disease, N Engl J Med, 331, 842, 10.1056/NEJM199409293311304 Greenberg, 1994, Oral budesonide for active Crohn's disease, N Engl J Med, 331, 836, 10.1056/NEJM199409293311303 Greenberg, 1996, Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study, Gastroenterology, 110, 45, 10.1053/gast.1996.v110.pm8536887 Lofberg, 1996, Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one-year study, Gut, 39, 82, 10.1136/gut.39.1.82 Singleton, 1993, Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial, Gastroenterology, 104, 1293, 10.1016/0016-5085(93)90337-C Candy, 1995, A controlled double blind study of azathioprine in the management of Crohn's disease, Gut, 37, 674, 10.1136/gut.37.5.674 Ewe, 1993, Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease, Gastroenterology, 105, 367, 10.1016/0016-5085(93)90709-L Feagan, 1995, Methotrexate for the treatment of Crohn's disease, N Engl J Med, 332, 292, 10.1056/NEJM199502023320503 Feagan, 2000, A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease, N Engl J Med, 342, 1627, 10.1056/NEJM200006013422202 Feagan, 1994, Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators, N Engl J Med, 330, 1846, 10.1056/NEJM199406303302602 Stange, 1995, European trial of cyclosporine in chronic active Crohn's disease: a 12-month study, Gastroenterology, 109, 774, 10.1016/0016-5085(95)90384-4 Jewell, 1995, Oral cyclosporine for chronic active Crohn's disease: a multicentre controlled trial, Eur J Gastroenterol Hepatol, 5, 499 Sutherland, 1991, in all categories except type of perianal dis Double blind, placebo controlled trial of metronidazole in Crohn's disease, Gut, 32, 1071, 10.1136/gut.32.9.1071 Rutgeerts, 1995, Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection, Gastroenterology, 108, 1617, 10.1016/0016-5085(95)90121-3 Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502 Sandler, 1988, Development of a Crohn's index for survey research, J Clin Epidemiol, 41, 451, 10.1016/0895-4356(88)90046-7 Faubion, 2001, Development of a simplified patient-based Crohn's Disease Activity Index (abstr), Gastroenterology, 120, A-273, 10.1016/S0016-5085(08)81354-6 Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804 Irvine, 1995, Usual therapy improves perianal Crohn's disease as measured by a new disease activity index, J Clin Gastroenterol, 20, 27, 10.1097/00004836-199501000-00008 Drossman, 1991, The rating form of IBD patient concerns: a new measure of health status, Psychosom Med, 53, 701, 10.1097/00006842-199111000-00010 Drossman, 1989, Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns, Dig Dis Sci, 34, 1379, 10.1007/BF01538073 Garrett, 1990, Health status in inflammatory bowel disease. Biological and behavioral considerations, Gastroenterology, 99, 90, 10.1016/0016-5085(90)91234-W Drossman, 1991, Health status and health care use in persons with inflammatory bowel disease. A national sample, Dig Dis Sci, 36, 1746, 10.1007/BF01296620 Drossman, 1992, Ulcerative colitis and Crohn's disease health status scales for research and clinical practice, J Clin Gastroenterol, 15, 104, 10.1097/00004836-199209000-00005 Drossman, 1994, Measuring quality of life in inflammatory bowel disease, Pharmacoeconomics, 6, 578, 10.2165/00019053-199406060-00010 Talal, 1995, Psychosocial factors in inflammatory bowel disease, Gastroenterol Clin North Am, 24, 699, 10.1016/S0889-8553(21)00219-3 Levenstein, 2001, Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease, Am J Gastroenterol, 96, 1822, 10.1111/j.1572-0241.2001.03878.x Mitchell, 1988, Quality of life in patients with inflammatory bowel disease, J Clin Gastroenterol, 10, 306, 10.1097/00004836-198806000-00014 Guyatt, 1989, A new measure of health status for clinical trials in inflammatory bowel disease, Gastroenterology, 96, 804, 10.1016/S0016-5085(89)80080-0 Love, 1992, Quality of life in inflammatory bowel disease, J Clin Gastroenterol, 14, 15, 10.1097/00004836-199201000-00005 Irvine, 1994, Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease, Gastroenterology, 106, 287, 10.1016/0016-5085(94)90585-1 Irvine, 1996, Does self-administration of a quality of life index for inflammatory bowel disease change the results?, J Clin Epidemiol, 49, 1177, 10.1016/0895-4356(96)00136-9 Irvine, 1996, The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial, Am J Gastroenterol, 91, 1571 Gregor, 1997, An evaluation of utility measurement in Crohn's disease, Inflamm Bowel Dis, 3, 265, 10.1097/00054725-199712000-00004 Gomes, 1986, Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease, Gut, 27, 92, 10.1136/gut.27.1.92 Olaison, 1990, Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation, Gut, 31, 325, 10.1136/gut.31.3.325 1987, Reproducibility of colonoscopic findings in Crohn's disease: a prospective multicenter study of interobserver variation. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID), Dig Dis Sci, 32, 1370, 10.1007/BF01296663 Mary, 1989, Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID), Gut, 30, 983, 10.1136/gut.30.7.983 Modigliani, 1990, Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Gastroenterology, 98, 811, 10.1016/0016-5085(90)90002-I Landi, 1992, Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives, Gastroenterology, 102, 1647, 10.1016/0016-5085(92)91725-J Cellier, 1994, Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives, Gut, 35, 231, 10.1136/gut.35.2.231 D'Haens, 1999, Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial, Gastroenterology, 116, 1029, 10.1016/S0016-5085(99)70005-3 Rutgeerts, 1984, Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery, Gut, 25, 665, 10.1136/gut.25.6.665 Rutgeerts, 1990, Predictability of the postoperative course of Crohn's disease, Gastroenterology, 99, 956, 10.1016/0016-5085(90)90613-6 Hellers, 1999, Oral budesonide for prevention of postsurgical recurrence in Crohn's disease, Gastroenterology, 116, 294, 10.1016/S0016-5085(99)70125-3 Ewe, 1999, Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial, Eur J Gastroenterol Hepatol, 11, 277, 10.1097/00042737-199903000-00011 Caprilli, 1994, Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC), Aliment Pharmacol Ther, 8, 35, 10.1111/j.1365-2036.1994.tb00158.x Brignola, 1995, Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease, Gastroenterology, 108, 345, 10.1016/0016-5085(95)90059-4 Florent, 1996, Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID), Eur J Gastroenterol Hepatol, 8, 229, 10.1097/00042737-199603000-00008 Lochs, 2000, Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI, Gastroenterology, 118, 264, 10.1016/S0016-5085(00)70208-3 Korelitz, 1998, Postoperative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multicenter trial (abstr), Gastroenterology, 114, A1011, 10.1016/S0016-5085(98)84115-2 Korelitz, 1984, Response to drug therapy in Crohn's disease: evaluation by rectal biopsy and mucosal cell counts, J Clin Gastroenterol, 6, 123, 10.1097/00004836-198404000-00005 D'Haens, 1998, Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum, Gastroenterology, 114, 262, 10.1016/S0016-5085(98)70476-7 D'Haens, 1999, Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine, Gastrointest Endosc, 50, 667, 10.1016/S0016-5107(99)80017-0 Baert, 1999, Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis, Gastroenterology, 116, 22, 10.1016/S0016-5085(99)70224-6 Farmer, 1975, Clinical patterns in Crohn's disease: a statistical study of 615 cases, Gastroenterology, 68, 627, 10.1016/S0016-5085(75)80270-8 Farmer, 1985, Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis, Gastroenterology, 88, 1818, 10.1016/0016-5085(85)90006-X Greenstein, 1988, Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms, Gut, 29, 588, 10.1136/gut.29.5.588 Sachar, 1992, Proposed classification of patient subgroups in Crohn's disease, Gastroenterology Int, 5, 141 Steinhart, 1998, Reliability of a Crohn's disease clinical classification scheme based on disease behavior, Inflamm Bowel Dis, 4, 228, 10.1097/00054725-199808000-00006 Gasche, 2000, A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998, Inflamm Bowel Dis, 6, 8, 10.1097/00054725-200002000-00002 Fredd, 1995, Standards for approval of new drugs for IBD, Inflamm Bowel Dis, 1, 284, 10.1097/00054725-199512000-00007 European Agency for the Evaluation of Medicinal Products Yaffe, 1983, Prognosis for nonoperative management of small-bowel obstruction in Crohn's disease, J Clin Gastroenterol, 5, 211, 10.1097/00004836-198306000-00003 Munkholm, 1994, Frequency of glucocorticoid resistance and dependency in Crohn's disease, Gut, 35, 360, 10.1136/gut.35.3.360 Faubion, 2001, The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study, Gastroenterology, 121, 255, 10.1053/gast.2001.26279 McLeod, 1997, Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease, Gastroenterology, 113, 1823, 10.1016/S0016-5085(97)70001-5 Vantrappen, 1990, Recurrence of Crohn's lesions in the neoterminal ileum after ileal resection and ileocolonic anastomosis, Verh K Acad Geneeskd Belg, 52, 373 Department of Health and Human Services Tremaine, 1994, A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis, J Clin Gastroenterol, 19, 278, 10.1097/00004836-199412000-00003 Prantera, 1999, Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial, Gastroenterology, 116, 521, 10.1016/S0016-5085(99)70172-1 Thomsen, 1998, A comparison of budesonide and mesalamine for active Crohn's disease, N Engl J Med, 339, 370, 10.1056/NEJM199808063390603 Campieri, 1997, Oral budesonide is as effective as oral prednisolone in active Crohn's disease, Gut, 41, 209, 10.1136/gut.41.2.209 Bar-Meir, 1998, Budesonide versus prednisone in the treatment of active Crohn's disease, Gastroenterology, 115, 835, 10.1016/S0016-5085(98)70254-9 Gross, 1996, Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease, Eur J Gastroenterol Hepatol, 8, 905 Sutherland, 1997, A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease, Gastroenterology, 112, 1069, 10.1016/S0016-5085(97)70117-3 Brignola, 1992, Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease, Dig Dis Sci, 37, 29, 10.1007/BF01308338 Prantera, 1992, Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease, Gastroenterology, 103, 363, 10.1016/0016-5085(92)90822-G Gendre, 1993, Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID), Gastroenterology, 104, 435, 10.1016/0016-5085(93)90411-5 Thomson, 1995, Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease, Aliment Pharmacol Ther, 9, 673, 10.1111/j.1365-2036.1995.tb00438.x Rutgeerts, 1999, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X McLeod, 1995, Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease, Gastroenterology, 109, 404, 10.1016/0016-5085(95)90327-5 Modigliani, 1996, Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives, Gastroenterology, 110, 688, 10.1053/gast.1996.v110.pm8608877 Cortot, 2001, Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease, Gut, 48, 186, 10.1136/gut.48.2.186 Gross, 1997, Replacement of systemic steroids by oral budesonide in patients with post-active or chronic Crohn's ileocolitis - a dose finding study (abstr), Gastroenterology, 112, A987 Gross, 1998, Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease, Gut, 42, 493, 10.1136/gut.42.4.493 Markowitz, 2000, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology, 119, 895, 10.1053/gast.2000.18144 Sandborn, 1999, Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease, Gastroenterology, 117, 527, 10.1016/S0016-5085(99)70445-2 Feagan, 2000, A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease (abstr), Gastroenterology, 118, A655, 10.1016/S0016-5085(00)84761-7 D'Haens, 1997, Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease, Gastroenterology, 112, 1475, 10.1016/S0016-5085(97)70027-1